Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA

  1. Felip, E.
  2. Cho, B.C.
  3. Gutiérrez, V.
  4. Alip, A.
  5. Besse, B.
  6. Lu, S.
  7. Spira, A.I.
  8. Girard, N.
  9. Califano, R.
  10. Gadgeel, S.M.
  11. Yang, J.C.-H.
  12. Yamamoto, S.
  13. Azuma, K.
  14. Kim, Y.J.
  15. Lee, K.-H.
  16. Danchaivijitr, P.
  17. Ferreira, C.G.
  18. Cheng, Y.
  19. Sendur, M.A.N.
  20. Chang, G.-C.
  21. Wang, C.-C.
  22. Prabhash, K.
  23. Shinno, Y.
  24. Stroyakovskiy, D.
  25. Paz-Ares, L.
  26. Rodriguez-Cid, J.R.
  27. Martin, C.
  28. Campelo, M.R.G.
  29. Hayashi, H.
  30. Nguyen, D.
  31. Tomasini, P.
  32. Gottfried, M.
  33. Dooms, C.
  34. Passaro, A.
  35. Schuler, M.
  36. Gelatti, A.C.Z.
  37. Owen, S.
  38. Perdrizet, K.
  39. Ou, S.-H.I.
  40. Curtin, J.C.
  41. Zhang, J.
  42. Gormley, M.
  43. Sun, T.
  44. Panchal, A.
  45. Ennis, M.
  46. Fennema, E.
  47. Daksh, M.
  48. Sethi, S.
  49. Bauml, J.M.
  50. Lee, S.-H.
  51. Show all authors +
Journal:
Annals of Oncology

ISSN: 1569-8041,  0923-7534

Year of publication: 2024

Volume: 35

Issue: 9

Pages: 805-816

Type: Article

DOI: 10.1016/J.ANNONC.2024.05.541 GOOGLE SCHOLAR lock_openOpen access editor
Data source: Scopus